Skip to main content
Multiple Sclerosis Discovery Forum
User Top Menu
Who We Are
How to Cite
News & Future Directions
Essays & Opinions
Meetings & Events
Clinical Trials - Public Availability of Results
MS trials baseline
Map of MS Prevalence
Progressive MS Authors Galaxy
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Scientific Literature TreeMap
Clinical Trials in MS
Click Here to Support MSDF
You are here
Most Viewed Papers
Elevated CSF neurofilament proteins predict brain atrophy: A 15-year follow-up study.
Scientists probe strategies to repair neuron damage in multiple sclerosis.
Analysis of Expenditure in Multiple Sclerosis Disease Modifying Therapies Evolution Between 2004-2013 in Spain.
Information processing speed in multiple sclerosis: Past, present, and future.
Systematic Review and Critique of Health Economic Models on Relapsing-Remitting Multiple Sclerosis in the UK.
All relapsing multiple sclerosis patients should be managed at a specialist clinic - YES.
Hippocampal expressions of metallothionein I/II and glycoprotein 96 in EAE-prone and EAE-resistant strains of rats.
Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis.
Comparison of a Markov Cohort Model and a Discrete-Event Simulation for Economic Analyses of Treatments for Multiple Sclerosis.
Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor.
A Study of Efficacy and Safety of Ocrelizumab in Patients with Relapse-Remitting Multiple Sclerosis
All relapsing multiple sclerosis patients should be seen in specialist clinics - NO.
Consent guidance: patients and doctors making decisions together
CellCept (Product Insert)
A fatal mycotic sepsis after retrograde intrarenal surgery: a case report and literature review.
Chronic pain disrupts the reward circuitry in multiple sclerosis.
A review of Neuropharmacology Effects of Nigella sativa and Its Main Component, Thymoquinone.
Efficacy of hematopoietic stem cell formultiple sclerosis, an evidence based meta-analysis.
Pharmacoeconomic Aspects of Multiple Sclerosis Treatments in Iran.
Roche and Biogen Idec decide to suspend Ocrelizumab treatment - Rheumatoid Arthritis development programme on hold
Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Biotinidase deficiency mimicking neuromyelitis optica beginning at the age of 4: A treatable disease.
A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod.
The complex role of estrogens in inflammation.
Novel Insights into the Multiple Sclerosis Risk Gene ANKRD55.